Eurobio Scientific Team

Press releases

2026

Eurobio Scientific finalizes the acquisition of CareDx’s Transplant Lab product division

July 1st, 2026

Eurobio Scientific Expands Oncology Portfolio with Genomic Assays for Urothelial Carcinoma and Cancer of Unknown or Uncertain Primary

May 26, 2026

Eurobio Scientific signs definitive agreement to acquire CareDx’s transplant lab product division

April 16, 2026

2025 Annual Results

April 10, 2026

FY 2025 revenue

January 27, 2026

Archive

Replacement of a Statutory Auditor

December 22,2025

Results for the first semester of fiscal year 2025

September 24, 2025

Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy

July 1st, 2025

Resultat Annuel 2024 - Growth of core business and strategic execution

April 28, 2025

Eurobio Scientific increases its footprint in Italy

March 12, 2025

Termination of the liquidity contract

March 3, 2025
French only

Calendar of financial publications 2025

Janvier 15, 2025 (FR)
French only

Eurobio Scientific: successful takeover bid at the end of its first period, reopening of the offer from 4 to 17 December

November 29, 2024 (FR)
French only

Opening of the public purchase offer until November 27

October 24, 2024 (FR)
French only

Eurobio Scientific: lifting of the last regulatory suspensive condition to the takeover bid project initiated by EB Development

October 16, 2024 (FR)
French only

Results for the first half of 2024

September 24, 2024

Eurobio Scientific completes acquisition of Endopredict® genomic test from Myriad Genetics

August 2, 2024

Suspension of the liquidity contract

August 1, 2024 (FR)
French only

First half 2024, a solid start of the financial year in an uncertain environment - PROPOSED TENDER OFFER

July 31, 2024

Agreement to acquire the ENDOPREDICT gene expression test for breast cancer

May 7, 2024

Publication of the 2023 financial annual report

April 26, 2024 (FR)
French only

2023 annual results, growth in Core Business and strategic deployment

April 9, 2024

2023 Annuel revenue at 130,1 MEUR

January 30, 2024

Capital reduction through cancellation of treasury shares-2024

January 9, 2024

Catherine Courboillet to join the Board as an Independant Member

November 7, 2023

Availability of the 2023 half-yearly financial report

October 30, 2023 (FR)
French only

GenDx reduces organ matching time to 3 hours

October 17, 2023
French only

H1 2023 Results: Solid performance of Core Business and acceleration of strategic deployment

October 11, 2023

Acceleration of strategic deployment in the first half of 2023

July 24, 2023

Capital reduction through cancellation of treasury shares

July 11, 2023

All resolutions approved at the 2023 Annual General Meeting - The Board of Directors appoints a new governance

June 16, 2023

Acquisition of D.I.D. in Italy

June 13, 2023

First IVDR CE marking of PCR tests

May 23, 2023

Publication of the 2022 annual financial report

April 28, 2023 (FR)

2022 annual results : very strong performance and strengthening of the Core Business

April 5, 2023

Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific

February 14, 2023

Eurobio Scientific formalises the appointment of Anne-Sophie Herelle as Group CFO

February 8, 2023

2022 annual turnover of €152.5M

January 23, 2023

H2 2022 report on the liquidity contract

January 5, 2023 (FR)

Exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer

November 22, 2022

Half-year financial report available

October 27, 2022 (FR)

H1 2022 Results: continued growth of non-COVID activity

October 11, 2022

Eurobio Scientific finalizes the acquisition of GenDx, international HLA diagnostics specialist

October 3, 2022

Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist

August 17, 2022

First half turnover of €83.6 million maintained at a high level

July 25, 2022

Half-year report on liquidity contract

July 11, 2022 (FR)

Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox

June 20, 2022

Eurobio Scientific's annual shareholders' meeting

June 14, 2022 (FR)

Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV

June 13, 2022

Closing of the Strategic Partnership with NEXTSTAGE AM

May 18, 2022

Availability of the 2021 annual financial report

April 28, 2022 (FR)

Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility

April 26, 2022

CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2

April 14, 2022

Maintaining high level results in 2021

April 6, 2022

New priority test for the detection of Omicron BA.x, BA.2 and Delta of SARS-CoV-2

February 7, 2022

Strategic partnership with NextStage AM

February 7, 2022

2021 TURNOVER : Exceptional level of €184.1million

January 24, 2022

Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France

January 11, 2022

Eurobio Scientific confirms its eligibility to the pea-pme system

January 10, 2022 (FR)

You may also like

Search

Retour en haut